# Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

> **NCT04796857** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Huiqiang Huang** · enrollment: 30 (estimated)

## Conditions studied

- Non-GCB/ABC Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Follicular Lymphoma Grade IIIb
- Transformed Lymphoma
- EBV-Positive DLBCL, Nos
- ALK-Positive Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** PD-1 Antibody
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04796857
- **Lead sponsor:** Huiqiang Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-31
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796857, "Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04796857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*